Rinvoq

Rinvoq (upadacitinib) is an oral, once-daily extended-release tablet that belongs to the class of drugs called JAK inhibitors. It is one of the most broadly approved medicines in this class, with FDA clearance for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, Crohn's disease, ulcerative colitis, and giant cell arteritis (GCA). As a pill, it offers a convenient alternative to injectable biologics for many patients with these conditions.

Rinvoq belongs to the JAK Inhibitors class of medications. Upadacitinib is a selective JAK1 inhibitor that blocks JAK-STAT signaling pathways involved in the inflammatory cascade driving multiple immune-mediated conditions, including rheumatoid arthritis, atopic dermatitis, and inflammatory bowel disease. Understanding how Rinvoq works helps explain both its benefits and its important safety considerations.

## What Rinvoq is used for

Rinvoq is prescribed for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Atopic dermatitis, Crohn's disease, Ulcerative colitis, and Giant cell arteritis. In each setting it is generally used when prior standard therapies (including TNF inhibitors for RA and biologics for IBD) have not provided adequate control. Rinvoq is available by prescription only and has been FDA-authorized since 2019.

## Dosage and administration

Typical adult dosing: RA/PsA/AS: 15 mg once daily. Atopic dermatitis: 15 mg or 30 mg once daily. Crohn's/UC: 45 mg once daily for 12 weeks (induction), then 15 or 30 mg once daily (maintenance). GCA: 15 mg once daily.

Rinvoq extended-release tablets are taken once daily with or without food. Tablets are swallowed whole — do not split, crush, or chew them. The induction dose for IBD is higher (45 mg) and is used for the first 12 weeks before stepping down to a maintenance dose. Never change your dose or stop Rinvoq without speaking to your prescriber.

## Side effects

Common side effects include Upper respiratory tract infections, Nausea, Acne, Herpes zoster (shingles), Elevated liver enzymes, and Neutropenia. Serious side effects include Serious infections including opportunistic infections, Blood clots (DVT, pulmonary embolism), Major adverse cardiovascular events (MACE), Malignancy, and Gastrointestinal perforation. Rinvoq carries a boxed warning about serious infections, cancer, cardiovascular events, thrombosis, and mortality — particularly in patients 50 and older with cardiovascular risk factors. These risks must be weighed individually with your prescriber.

## Managing common side effects

• Upper respiratory infections: rest, stay hydrated, and contact your clinician if symptoms worsen or you develop fever.
• Nausea: eat small, frequent meals and take the tablet with food if this helps.
• Acne: use gentle skincare; discuss topical treatments with your prescriber if needed.
• Herpes zoster (shingles): vaccination is recommended before starting; notify your clinician promptly if a painful rash appears.
• Elevated liver enzymes: your clinician will monitor labs; avoid excessive alcohol.

## Warnings and precautions

Key precautions: Boxed warning: serious infections, malignancy, MACE, thrombosis, and mortality risk in patients ≥50 with cardiovascular risk factors; Screen for TB, viral hepatitis, and CBC before initiating; Contraindicated in pregnancy. Discuss the complete risk profile with your prescriber before starting Rinvoq, especially if you are over 50, smoke, or have a history of cardiovascular disease or cancer.

## Drug interactions

Rinvoq can interact with Strong CYP3A4 inhibitors (major) — increase upadacitinib exposure; Strong CYP3A4 inducers (major) — decrease upadacitinib exposure; Live vaccines (major) — avoid during therapy. Always inform your prescriber and pharmacist of every medication and supplement you take.

## Cost, coverage, and savings

Rinvoq is a brand-name specialty medication with significant list-price cost. AbbVie offers a myAbbVie Assist savings program and copay cards for eligible patients. Searching for a rinvoq copay card, rinvoq savings card, or rinvoq patient assistance through the official AbbVie website is the best path to cost support. Medicare patients should ask about extra help programs.

## How Rinvoq compares to alternatives

Rinvoq competes with other JAK inhibitors (Xeljanz/tofacitinib, Olumiant/baricitinib) and with injectable biologics (Humira, Entyvio, Skyrizi). For ulcerative colitis, head-to-head data favor Rinvoq over Entyvio in some measures of remission. For atopic dermatitis, Rinvoq and Dupixent represent different mechanism options (JAK inhibition vs. IL-4/13 blockade). The best choice depends on the specific condition, prior treatment, risk tolerance, and preference for oral vs. injectable therapy.

## Monitoring and lifestyle

Before starting Rinvoq, baseline CBC, liver function, lipids, TB screening, and hepatitis B/C testing are standard. During treatment, periodic CBC, liver enzymes, and lipid panels are monitored. Shingles vaccination before starting is recommended where feasible. Avoid live vaccines during treatment.

## What to expect from treatment

Many patients notice improvement in symptoms within 2–4 weeks, with continued gains over the first 3–6 months. For IBD, response is assessed at week 12 of induction. Rinvoq is taken long-term for most conditions — do not stop without your prescriber's guidance.

## Before you start Rinvoq

A complete pre-treatment workup includes TB test, hepatitis screening, CBC, and a thorough medication review. Effective contraception is required throughout treatment due to the contraindication in pregnancy. Update all vaccines before starting if possible, since live vaccines cannot be given during therapy.

## Missed dose and overdose

If you miss a dose of Rinvoq, take it as soon as you remember the same day. If you don't remember until the next day, skip the missed dose and resume your regular schedule. Never take two doses in one day. If overdose is suspected, contact poison control or emergency services.

## Use in specific populations

Pregnancy: Contraindicated — use effective contraception. Breastfeeding: Not recommended. Older adults (≥50): The boxed warning applies most prominently to this group, especially those with cardiovascular risk factors. Kidney/liver impairment: Dose adjustment may be needed for severe impairment.

## When to contact your doctor

Contact your clinician for signs of infection (fever, chills, persistent cough), unexplained weight loss, leg swelling or pain (possible clot), chest pain, or any new skin growth. Do not stop Rinvoq abruptly without guidance.

## Storage and handling

Store at room temperature, 20–25°C (68–77°F). Keep in original container and protect from moisture. Check expiration dates and dispose of expired tablets through a take-back program.

## Clinical evidence and effectiveness

The SELECT program of phase 3 trials demonstrated Rinvoq's efficacy across its approved indications. In SELECT-COMPARE (RA), Rinvoq outperformed adalimumab on ACR50 response. In U-ACHIEVE (UC) and U-EXCEL (Crohn's), robust induction and maintenance remission rates supported approval. The HEADS UP trial showed Rinvoq superior to dupilumab on certain atopic dermatitis endpoints at week 16. Your prescriber can translate these data to your individual situation.

## Key takeaways

• Rinvoq is an oral JAK1 inhibitor with the broadest indication set in its class.
• A boxed warning covers serious infections, cancer, MACE, thrombosis, and death, especially for patients ≥50 with CV risk.
• TB screening, hepatitis testing, and CBC are required before starting.
• Contraception is required throughout treatment; Rinvoq is contraindicated in pregnancy.
• Manufacturer assistance programs can substantially reduce cost.

## Medical disclaimer

This article about Rinvoq (upadacitinib) is for general education and is not a substitute for professional medical advice, diagnosis, or treatment. Always follow the guidance of your physician or pharmacist and the instructions on your prescription label.